| Drug Name |
Levocarnitine |
| Drug ID |
BADD_D01271 |
| Description |
Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. |
| Indications and Usage |
For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease. |
| Marketing Status |
approved; investigational |
| ATC Code |
A16AA01 |
| DrugBank ID |
DB00583
|
| KEGG ID |
D02176
|
| MeSH ID |
D002331
|
| PubChem ID |
10917
|
| TTD Drug ID |
D0G8SQ
|
| NDC Product Code |
81999-0005; 50383-171; 50383-172; 54482-147; 54482-148; 54482-145; 54482-144; 0143-9852; 52817-830; 58116-010; 59380-018; 64980-503; 0517-1045; 51927-0240; 70954-492; 49452-1778; 51927-1865; 16571-762; 58159-089; 42765-049; 76055-1005 |
| UNII |
0G389FZZ9M
|
| Synonyms |
Carnitine | Levocarnitine | Vitamin BT | L-Carnitine | L Carnitine | Bicarnesine |
